Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + remdesivir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of dexamethasone (a corticosteroid) and remdesivir (an antiviral). Dexamethasone reduces inflammation while remdesivir inhibits viral RNA-dependent RNA-polymerase, blocking SARS-CoV-2 replication. This combination targets both the inflammatory response and viral replication aspects of COVID-19 pathophysiology. Studies have shown this combination may reduce intubation rates and mortality in hospitalized COVID-19 patients compared to dexamethasone alone.
02
Targets
GR (Glucocorticoid receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on dexamethasone + remdesivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + remdesivir.